Skip to content

Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public

Evidence · subcategory

Trials

Individual randomised trials: design, population, endpoints, results, and limitations.

33 topics1,574 posts10 solved Moderators: j.mwangi, bench_notes About this category

randomised trial estimand intention to treat discontinuation & dropout open label surrogate endpoints

33 topics · page 2 of 2

Topic	Participants	Replies	Views	Activity
Follow-up: Open-label extensions: what survives and what does not open label intention to treat surrogate endpoints estimand Solved Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and…	+22	26	397	16mo
Reading a supplementary appendix and finding the interesting part open label discontinuation & dropout intention to treat estimand Reading a supplementary appendix and finding the interesting part — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do…	+87	92	1.1k	17mo
[2026 update] How to read a forest plot, properly, from scratch estimand discontinuation & dropout surrogate endpoints Solved How to read a forest plot, properly, from scratch — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it before…	+49	53	643	19mo